最新医学別冊　診断と治療のABC136　統合失調症

出版社： 最新医学社
発行日： 2018-07-01
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： 統合失調症
電子書籍版： 2018-07-01
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

目次

  • 序論

    第１章　概念と疫学
    　概念の歴史
    　DSM−5の診断基準
    　症候学
    　統合失調症の経過と予後
    　疫学
    　コラム：映画で学ぶ統合失調症

    第２章　病態
    　統合失調症の遺伝子研究
    　ブレインバンクと死後脳研究
    　神経生理
    　神経薬理学的病態仮説
    　動物モデル
    　脳機能画像を用いた統合失調症の病態評価
    　　－fMRI・PETによる知見を中心に－
    　神経心理・認知機能
    　精神病理学的諸仮説

    第３章　治療・支援
    　薬物治療の基本
    　治療抵抗性の病態　－重症例への対応，電気けいれん療法とクロザピンを中心に－
    　精神療法 －支持的精神療法・認知行動療法－
    　認知機能リハビリテーション，ソーシャルスキルストレーニング（SST）
    　就労支援
    　統合失調症薬物治療ガイドライン
    　コラム：日本人統合失調症患者の身体リスク

    第４章　法との関連
    　精神保健福祉法
    　医療観察法
    　統合失調症と自動車運転関連法規
    　当事者研究
    　精神鑑定 －刑事精神鑑定・成年後見制度－
    　コラム：当事者研究の現在

    第５章　まとめ
    　統合失調症の臨床・研究の今後

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念と疫学

P.15 掲載の参考文献
1) Kuchenhoff B : Vorwort zur neuen Ausgabe. In : Dementia praecox oder Gruppe der Schizophrenien. Mit einem Vorwort von Bernhard Kuchenhoff (Bleuler E). Pscyhosozial-Verlag, 2014. (Franz Deuticke, 1911)
 
2) Kehlmann D : Die Vermessung der Welt. Rowohlt, Reinbek bei Hamburg, 2005.
 
3) 山岸洋 : パラノイア・妄想性障害. 臨精神医 42 : 21-24, 2013.
 
4) Jaspers K : Allgemeine Psychopathologie. Springer, Berlin, 1913.
 
5) Kendler K S, et al : Criticism of Kraepelin's psychiatric nosology : 1896-1927. AJP in Advance (doi : 10.1176/appi.ajp.2017.17070730).
 
6) Gruhle H W : Bleulers Schizophrenie und Kraepelins Dementia praecox. Z. f, d. g. Neurol Psychiat 17 : 114-133, 1913.
 
P.22 掲載の参考文献
1) Professional Staff of the United States-United Kingdom Cross-National Project : The diagnosis and psychopathology of schizophrenia in New York and London. Schizophr Bull 11 : 80-102, 1974.
 
2) Tandon R, et al : Definition and description of schizophrenia in the DSM-5. Schizophr Res 150 (1) : 3-10, 2013.
PubMed
3) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders : DSM-5. Am Psychiatric Pub Incorporated, 2013.
 
P.30 掲載の参考文献
1) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders 5th Ed. APA, Washington DC, 2013.
 
2) World Health Organization : The ICD-10 Classification of Mental and Behavioural Disorders. WHO, Geneva 1992.
 
3) Yung A, et al : Treating Schizophrenia in the Prodromal Phase. Taylor & Francis, London, 2004.
 
4) Jaspers K : Allgemeine Psychopathologie. Neunte, unveranderte Aufl. Springer, Berlin Heidelberg New York, 1973.
 
5) Schneider K : Klinische Psychopathologie. 15. Aufl. mit einem aktualisierten und erweiterten Kommentar von Huber G und Gross G. Thieme, Stuttgart, 2007 (針間博彦訳, クルト・シュナイダー 新版 臨床精神病理学. 文光堂, 東京, 2007).
 
6) 永田俊彦, 他 : 慢性期症状. 臨床精神医学講座 2 精神分裂病 I (松下正明総編集), pp375-388. 中山書店, 東京, 1999.
 
7) Bleuler E : Dementia praecox oder Gruppe der Schizophrenien. Franz Deutike, 1911 (飯田真, 他 : 早発性痴呆または精神分裂病群. 医学書院, 1974).
 
P.36 掲載の参考文献
1) Lieberman J A, et al : The early stages of schizophrenia : speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50 : 884-897, 2001.
PubMed
2) Bleuler M : The long-time course of the schizophrtenic psychoses. Psychol Med 4 : 244-254, 1974.
 
3) Jaaskelainen E, et al : A systematic review and meta-anaiysis of recovery in schizophrenia. Schizophr Bull 39 : 1296-1306, 2013.
 
4) van der Heiden, et al : Course and outcome. In : Schizophrenia (Weinberger D R, et al, eds), p104-141. Blackwell Publishing, Oxford, 2011.
 
5) Andreasen N C, et al : Remission in schizophrenia : proposed criteria and rationale for consensus. Am J Psychiatry 162 : 441-449, 2005.
PubMed
6) Hafner H, et al : The course of schizophrenia in the light of modern follow-up studies : the ABC and WHO studies. Eur Arch Psychiatry Clin Meurosci 249 (Suppl 4) : IV/14-IV/26, 1999.
 
7) Fusar-Poli P, et al : Predicting psychosis : meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69 : 220-229, 2012.
PubMed
8) Lin A, et al : Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry 172 : 249-258, 2015.
 
9) Gaebel W, et al : Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophr Res 152 : 478-486, 2014.
 
10) Arndt S, et al : A longitudinal study of symptom dimensions in schizophrenia : prediction and patterns of change. Arch Gen Psychiatry 52 : 352-360, 1995.
PubMed
11) Demjaha A, et al : Antipsychotic treatment resistance in first-episode psychosis : prevalence, subtypes and predictors. Psychol Med 47 : 1981-1989, 2017.
PubMed
12) Penttila M, et al : Duration of untreated psychosis as predictor of long-term outcome in schizophrenia : systematic review and meta-analysis. Br J Psychiatry 205 : 88-94, 2014.
PubMed
13) Birchwood M, et al : Early intervention in psychosis : the critical period hypothesis. Br J Psychiatry 172 (suppl. 33) : 53-59, 1998.
 
14) Moller H-J, et al : The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders : comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur Arch Psychiatry Clin Neurosci 260 : 367-384, 2010.
 
15) Rosen C, et al : Diagnostic and prognostic significance of Schneiderian first-rank symptoms : a 20-year longitudinal study of schizophrenia and bipolar disorder. Compr Psychiatry 52 : 126-131, 2011.
PubMed
16) Goghari V M, et al : A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders. Psychol Med 43 : 1151-1160, 2013.
PubMed
17) Wiersma D, et al : Natural course of schizophrenic disorders : a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 24 : 75-85, 1998.
 
18) Meier H M, et al : Neuropsychological decline in schizophrenia from the premorbid to the postonset period : evidence from a population-representative longitudinal study. Am J Psychiatry 171 : 91-101, 2014.
 
19) Velthorst E, et al : Developmental trajectories of impaired community functioning in schizophrenia. JAMA Psychiatry 73 : 48-55, 2016.
PubMed
20) Becker H E, et al : Neurocognitive functioning before and after the first psychotic episode : does psychosis result in cognitive deterioration? Psychol Med 40 : 1599-1606, 2010.
PubMed
21) Szoke A, et al : Longitudinal studies of cognition in schizophrenia : meta-analysis. Br J Psychiatry 192 : 248-257, 2008.
PubMed
22) Bonner-Jackson A, et al : Neurocognition in schizophrenia : a 20-year multi-follow-up of the course of processing speed and stored knowledge. Compr Psychiatry 51 : 471-479, 2010.
PubMed
23) Friedman J I, et al : Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia : a comparison with Alzheimer's disease and normal aging. Am J Psychiatry 158 : 1441-1448, 2001.
PubMed
24) 鈴木道雄 : 脳画像の発展は統合失調症の理解に何をもたらしたのか? 精神医 59 : 1101-1106, 2017.
 
25) van Haren N E M, et al : Progressive brain volume loss in schizophrenia over the course of the illness : evidence of maturational abnormalities in early adulthood. Biol Psychiatry 63 : 106-113, 2008.
PubMed
26) Fusar-Poli P, et al : Improving outcomes of first-episode psychosis : an overview. World Psychiatry 16 : 251-265, 2017.
PubMed
27) Millan M J, et al : Altering the course of schizophrenia : progress and perspectives. Nat Rev Drug Discov 15 : 485-515, 2016.
PubMed
P.43 掲載の参考文献
1) MacMahon B, et al : Epidemiology : Principles and Methods. Little Brown and Company, Boston, 1970.
 
2) Tandon R, et al : Schizophrenia, "Just the Facts" What we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102 : 1-18, 2008.
PubMed
3) 福田正人, 他 : 統合失調症. 医学書院, 東京, 2013.
 
4) Bleuler E : Dementia Praecox, or the group of Schizophrenias (Zinkin J, tras), 1911. International University Press, New York, 1950.
PubMed
5) Kraepelin E : 1971. In : Dementia Praecox and Paraphrenia (Robertson G M, Ed). New York, Krieger, 1919.
 
6) Jeste D V, et al : Did schizophrenia exist before the 18th century? Compr Psychiatry 26 : 493-503, 1985.
 
7) Ellard J : Did schizophrenia exist before the 18th century. Aust N Z J Psychiatry 21 : 306-314, 1987.
PubMed
8) Evans K, et al : Searching for schizophrenia in ancient Greek and Roman literature : a systematic review. Acta Psychiatr Scand 107 : 323-330, 2003.
PubMed
9) Torrey E F : Schizophrenia and Civilization. Jason Aronson, New York, 1980.
 
10) Hare E H : Schizophrenia as a recent disease. Br J Psychiatry 153 : 521-531, 1988.
 
11) Crow T J : A continuum of psychosis, one human gene, and not much else-the case for homogeneity. Schizophr Res 17 : 135-145, 1995.
 
12) Bleuler M : The Schizophrenic Disorders. Yale University Press, New Haven, 1972.
 
13) Hegarty J D, et al : One hundred years of schizophrenia : a meta-analysis of the outcome literature. Am J Psychiatry 151 : 1409-1416, 1994.
PubMed
14) Morrison J R : Changes in subtype diagnosis of schizophrenia : 1920-1966. Am J Psychiatry 131 : 674-677, 1974.
PubMed
15) Stompe T, et al : Are we witnessing the disappearance of catatonic schizophrenia? Compr Psychiatry 43 : 167-174, 2002.
PubMed
16) Eagles J M, et al : Decline in the diagnosis of schizophrenia among first contacts with psychiatric services in north-east Scotland, 1969-1984. Br J Psychiatry 152 : 793-798, 1988.
PubMed
17) Woogh C : Is schizophrenia on the decline in Canada? Can J Psychiatry 46 : 61-67, 2001.
PubMed
18) Tsuchiya K J, et al : First-admission rates of schizophrenia in Denmark, 1980-1997 : have they been increasing? Schizophr Res 54 : 187-191, 2002.
PubMed
19) Bray I, et al : Increase in schizophrenia incidence rates : findings in a Canadian cohort born 1975-1985. Soc Psychiatry Psychiatr Epidemiol 41 : 611-618, 2006.
 
20) Stromgren E : Changes in the incidence of schizophrenia. Br J Psychiatry 150 : 1-7, 1987.
PubMed
21) Kendell R E, et al : The problem of detecting changes in the incidence of schizophrenia. Br J Psychiatry 162 : 212-218, 1993.
PubMed
22) World Health Organization : The Global Burden of Disease 2004 Update, 2004.
 
23) Sartorius N, et al : Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol Med 16 : 909-926, 1986.
PubMed
24) Jablensky A, et al : Schizophrenia : manifestations, incidence, and course in different cultures. Psychol Med 22 (Suppl 20) : 1-97, 1992.
 
25) World Health Organization : The International Statistical Classification of Diseases and Related Health Problems, Ninth Revision (ICD-9) -Section V. Mental and Behavioral Disorders. World Health Organization, Geneva, 1978.
 
26) Wing J K, et al : The Measurement and Classification of Psychiatric Symptoms. Cambridge University Press, London, 1974.
 
27) McGrath J, et al : A systematic review of the incidence of schizophrenia BMC Med 2 : 13, 2004.
 
28) McGrath J, et al : Schizophrenia : a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30 : 67-76, 2008.
PubMed
29) Cantor-Graae E : The contribution of social causes to schizophrenia : a review of recent findings. Can J Psychiatry 52 : 277-286, 2007.
PubMed
30) Saha S, et al : A systematic review of the prevalence of schizophrenia. PLoS Med 2 : 413-433, 2005.
 
31) Perala J, et al : Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64 : 19-28, 2007.
 
32) Seeman MV : Gender differences in schizophrenia. Can J Psychiatry 27 : 107-112, 1982.
PubMed
33) Aleman A, et al : Sex differences in the risk of schizophrenia : evidence from meta-analysis. Arch Gen Psychiatry 60 : 565-571, 2003.
PubMed
34) Beauchamp G, et al : Influence of diagnostic classification on gender ratio in schizophrenia. A meta-analysis of youths hospitalized for psychosis. Soc Psychiatry Psychiatr Epidemiol 39 : 1017-1022, 2004.
PubMed
35) Hambrecht M, et al : Evidence for a gender bias in epidemiological studies of schizophrenia. Schizophr Res 8 : 223-231, 1992.
 
36) McGrath J J : The surprisingly rich contours of schizophrenia epidemiology. Arch Gen Psychiatry 64 : 14-16, 2007.
PubMed
37) Kendler K S, et al : The Roscommon family study. 1. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry 50 : 527-540, 1993.
PubMed
38) Heston L L : Psychiatric disorders in the foster home reared children of schizophrenic mothers. Br J Psychiatry 112 : 819-825, 1966.
PubMed
39) Kety S S, et al : The types and prevalence of mental illness in the biological and adoptive families of adopted schizophrenics, J Psychiatr Res 1 : 345-362, 1968.
 
40) Gottesman I I, et al : Clinical genetics as clues to the "real" genetics of schizophrenia. Schizophr Bull 13 : 23-47, 1987.
 
41) Sullivan P F, et al : Schizophrenia as a complex trait : evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 60 : 1187-1192, 2003.
PubMed
42) Cannon T D, et al : The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry 55 : 67-74, 1998.
 
43) Cardno A G, et al : Heritability estimates for psychotic disorders : the Maudsley twin psychosis series. Arch Gen Psychiatry 56 : 162-168, 1999.
PubMed
44) Maki P, et al : Predictors of schizophrenia-a review. Br Med Bull 73/74 : 1-15, 2005.
 
45) Penner J D, et al : Prenatal infectious and nutritional factors and risk of schizophrenia. Expert Rev Neurotherapeutics 7 : 797-805, 2007.
 
46) Meyer U, et al : The neurodevelopmental impact of prenatal infections at different times in pregnancy : the earlier the worse. Neuroscientist 13 : 241-266, 2007.
PubMed
47) Mednick S A, et al : Adult schizophrenia following exposure to an influenza epidemic. Arch Gen Psychiatry 45 : 189-192, 1988.
 
48) Brown A S, et al : Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol Psychiatry 49 : 473-486, 2001.
PubMed
49) Brown A S, et al : Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry 162 : 767-773, 2002.
 
50) Ashdown H, et al : The role of cytokines in mediating effects of prenatal infection in the fetus : implications for schizophrenia. Mol Psychiatry 11 : 47-55, 2006.
PubMed
51) Susser E, et al : Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry 53 : 25-31, 1996.
PubMed
52) St Clair D, et al : Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-61. JAMA 294 : 557-562, 2005.
 
53) Khashan A S, et al : Higher risk of offspring schizophrenia following antenatal exposure to serious adverse life events. Arch Gen Psychiatry 65 : 146-152, 2008.
 
54) Koenig J I, et al : Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring Potential relevance to schizophrenia. Behav Brain Res 156 : 251-256, 2005.
PubMed
55) Yuii K, et al : Stress sensitization in schizophrenia. Ann N Y Acad Sci 1113 : 276-290, 2007.
PubMed
56) Lipska B K, et al : Postpubertal emergence of hyperresponsiveness to stress and to arnphetamine after neonatal excitotoxic hippocampal damage : a potential animal model of schizophrenia. Neuropsychopharmacology 9 : 67-75, 1993.
 
57) Geddes J R, et al : Obstetric complications and schizophrenia : ameta-analysis. Br J Psychiatry 167 : 786-793, 1995.
 
58) Cannon M, et al : Obstetrical complications and schizophrenia : historical and meta-analytic review. Am J Psychiatry 159 : 1080-1092, 2002.
PubMed
59) Byrne M, et al : Obstetric conditions and risk of first admission with schizophrenia : a Danish national register based study. Schizophr Res 97 : 51-59, 2007.
PubMed
60) Geddes J R, et al : Schizophrenia and complications of pregnancy and labor : an individual patient data meta-analysis. Schizophr Bull 25 : 413-423, 1999.
PubMed
61) Malaspina D, et al : Advancing paternal age and the risk of schizophrenia. Arch Gen Psychiatry 58 : 361-367, 2001.
PubMed
62) Byrne M, et al : Parental age and risk of schizophrenia : a case-control study. Arch Gen Psychiatry 60 : 673-678, 2003.
PubMed
63) Wohl M, et al : Paternal ages below or above 35 years old are associated with a different risk of schizophrenia in the offspring. Eur Psychiatry 22 : 22-26, 2007.
PubMed
64) Cheng J Y, et al : Meta-regression analysis using latitude as moderator of paternal age related schizophrenia risk. Schizophr Res 99 : 71-76, 2008.
PubMed
65) Perrin M C, et al : Aberrant epigenetic regulation could explain the relationship of paternal age to schizophrenia. Schizophr Bull 33 : 1270-1273, 2007.
PubMed
66) Torrey E F, et al : Seasonality of birth in schizophrenia and bipolar disorder : a review of the literature. Schizophr Res 28 : 1-38, 1997.
PubMed
67) McGrath J J, et al : Season of birth and schizophrenia : a systematic review and meta-analysis of data from the Southern Hemisphere. Schizophr Res 35 : 237-242, 1999.
PubMed
68) Davies G, et al : A systematic review and meta-analysis of northern hemisphere season of birth studies in schizophrenia. Schizophr Bull 29 : 587-593, 2003.
 
69) Lewis M S : Age incidence and schizophrenia : Part 1. The season of birth controversy. Schizophr Bull 15 : 59-73, 1989.
PubMed
70) Read J, et al : Childhood trauma, psychosis, and schizophrenia a literature review with theoretical and clinlcal implications. Acta Psychiatr Scand 112 : 330-350, 2005.
 
71) Morgan C, et al : Environmental factors in schizophrenia : childhood trauma-a critical review. Schizophr Bull 33 : 3-10, 2007.
PubMed
72) Wilcox J A, et al : Childhood head trauma and psychosis. Psychiatry Res 21 : 303-306, 1987.
PubMed
73) David A S, et al : Psychosis following head injury : a critical review. J Neurol Neurosurg Psychiatry 76 (Suppl 1) : 453-460, 2005.
 
74) Morgan C, et al : Parental separation, loss and psychosis in different ethnic groups : a case-control study. Psychol Med 37 : 495-503, 2006.
 
75) Tienari P, et al : Genotype-environment interaction in schizophrenia spectrum disorder. Long-term follow-up study of Finnish adoptees. Br J Psychiatry 184 : 216-222, 2004.
PubMed
76) Dalman C, et al : Infection in the CNS during childhood and the risk of subsequent psychotic illness : a cohort study of more than one million Swedish subjects. Am J psychiatry 165 : 59-65, 2008.
PubMed
77) Semple D M, et al : Cannabis as a risk factor for psychosis : systematic review. J Psychopharmacol 19 : 187-194, 2005.
 
78) Moore T H M, et al : Cannabis use and risk of psychotic or affective mental health outcomes : a systematic review. Lancet 370 : 319-328, 2007.
PubMed
79) Degenhardt L, et al : Is cannabis use a contributory cause of psychosis? Can J Psychiatry 51 : 566-574, 2006.
PubMed
80) Barnes T R E, et al : Comorbid substance abuse and age of onset of schizophrenia. Br J Psychiatry 188 : 237-242, 2006.
PubMed
81) Norman R M G, et al : Stressful life events and schizophrenia I : areview of the research. Br J Psychiatry 162 : 161-166, 1993.
 
82) Harrison G : Trajectories of psychosis : towards a new social biology of schizophrenia. Epidemiol Psichiatr Soc 13 : 152-157, 2004.
PubMed
83) Allardyce J, et al : Review : the wider social environment and schizophrenia. Schizophr Bull 32 : 592-598, 2006.
PubMed
84) Walker E, et al : Prediction of adult-onset schizophrenia from childhood home movies of the patients. Am J Psychiatry 147 : 1052-1056, 1990.
 
85) Fish B, et al : Infants at risk for schizophrenia : sequelae of a genetic neurointegrative defect. A review and replication analysis of pandysmaturation in the Jerusalem Infant Development Study. Arch Gen Psychiatry 49 : 221-235, 1992.
PubMed
86) Jones P, et al : Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344 : 1398-1402, 1994.
PubMed
87) Cornblatt B, et al : Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 11 : 487-508, 1999.
PubMed
88) Cannon M, et al : Evidence for early childhood, pan-development impairment specific to schizophreniform disorder : results from a longitudinal birth cohort. Arch Gen Psychiatry 59 : 449-456, 2002.
PubMed
89) Keshavan M S, et al : Premorbid indicators and risk for schizophrenia : a selective review and update. Schizophr Res 79 : 45-57, 2005.
PubMed
90) Hill A B : The environment and disease : association or causation. Proc R Soc Med 58 : 295-300, 1965.
 

第2章 病態

P.53 掲載の参考文献
1) Allen N C, et al : Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia : the SzGene database. Nat Genet 40 (7) : 827-834, 2008.
PubMed
2) Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium : Genome-wide association study identifies five new schizophrenia loci. Nat Genet 43 (10) : 969-976, 2011.
PubMed
3) Ripke S, et al : Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45 (10) : 1150-1159, 2013.
PubMed
4) Schizophrenia Working Group of the Psychiatric Genomics Consortium : Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (7510) : 421-427, 2014.
 
5) Purcell S M, et al : A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506 (7487) : 185-190, 2014.
PubMed
6) Rees E, et al : Analysis of exome sequence in 604 trios for recessive genotypes in schizophrenia. Transl Psychiatry 5 : e607, 2015.
PubMed
7) Genovese G, et al : Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nat Neurosci 19 (11) : 1433-1441, 2016.
 
8) Singh T, et al : Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 19 (4) : 571-577, 2016.
 
9) Takata A, et al : De Novo Synonymous Mutations in Regulatory Elements Contribute to the Genetic Etiology of Autism and Schizophrenia. Neuron 89 (5) : 940-947, 2016.
 
10) Kato T : Whole genome/exome sequencing in mood and psychotic disorders. Psychiatry Clin Neurosci 69 (2) : 65-76, 2015.
PubMed
P.60 掲載の参考文献
1) PGC-SCZ : Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (7510) : 421-427, 2014.
 
2) Fromer M, et al : De novo mutations in schizophrenia implicate synaptic networks. Nature 506 (7487) : 179-184, 2014.
PubMed
3) Purcell S M, et al : A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506 (7487) : 185-190, 2014.
PubMed
4) 國井泰人, 他 : 生前登録システムに基づく精神疾患ブレインバンクの取り組み. 医のあゆみ 261 (10) : 969-975, 2017.
 
5) ブレインバンク倫理指針 <http://www.jsbp.org/2015/1529/>.
 
6) 丹羽真一, 他 : 統合失調症死後脳研究. 臨精薬理 12 : 148-168, 2009.
 
7) Sakai M, et al : Assessment of copy number variations in the brain genome of schizophrenia patients. Mol Cytogenet 8 : 46, 2015.
PubMed
8) Horvath S, et al : Analyzing schizophrenia by DNA microarrays. Biol Psychiatry 69 (2) : 157-162, 2011.
PubMed
9) Darby M M, et al : Consistently altered expression of gene sets in postmortem brains of individuals with major psychiatric disorders. Transl Psychiatry 6 (9) : e890, 2016.
PubMed
10) Takata, A, et al : Genome-wide identification of splicirlg QTLs in the human brain and their enrichment among schizophrenia-associated loci. Nat Commun 8 : 14519, 2017.
PubMed
11) Abdolmaleky H M, et al : Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients : a preliminary report. Am J Med Genet B Neuropsychiatr Genet 134B (1) : 60-66, 2005.
PubMed
12) Iwamoto K, et al : DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci 25 (22) : 5376-5381, 2005.
PubMed
13) Roussos P, et al : A role for noncoding variation in schizophrenia. Cell Rep 9 (4) : 1417-1429, 2014.
 
14) Numata S, et al : DNA methylation changes in the postmortem dorsolateral prefrontal cortex of patients with schizophrenia. Front Genet 5 : 280, 2014.
PubMed
15) Wockner L F, et al : Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl Psychiatry 4 : e339, 2014.
PubMed
16) Akbarian S, et al : The PsychENCODE project. Nat Neurosci 18 (12) : 1707-1712, 2015.
PubMed
17) Davalieva K, et al : Proteomics Research in Schizophrenia. Front Cell Neurosci 10 : 18, 2016.
PubMed
18) Nascimento J M, et al : The proteome of schizophrenia. NPJ Schizophr 1 : 14003, 2015.
PubMed
19) Hirayama-Kurogi M, et al : Downregulation of GNA13-ERK network in prefrontal cortex of schizophrenia brain identified by combined focused and targeted quantitative proteomics. J Proteomics 158 : 31-42, 2017.
PubMed
20) Horrobin D F, et al : Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 30 (8) : 795-805, 1991.
PubMed
21) Komoroski R A, et al : Phospholipid abnormalities in postmortem schizophrenic brains detected by 31P nuclear magnetic resonance spectroscopy : a preliminary study. Psychiatry Res 106 (3) : 171-180, 2001.
PubMed
22) Matsumoto J, et al : Decreased 16 : 0/20 : 4-phosphatidylinositol level in the post-mortem prefrontal cortex of elderly patients with schizophrenia. Sci Rep 7 : 45050, 2017.
 
23) Kunii Y, et al : Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35 (4) : 1139-1143, 2011.
PubMed
24) Nishiura K, et al : Profiles of DARPP-32 in the Insular Cortex with Schizophrenia : A Postmortem Brain Study. Prog Neuropsychopharmacol Biol Psychiatry 35 (8) : 1901-1907, 2011.
PubMed
25) Kunii Y, et al : Detailed DARPP-32 Expression Profiles in Post-mortem Brains from Patients with Schizophrenia : An Immunohistochemical Study. Med Mol Morphol 44 (4) : 190-199, 2011.
 
26) Kleinman J E, et al : Genetic neuropathology of schizophrenia : new approaches to an old question and new uses for postmortem human brains. Biol Psychiatry 69 (2) : 140-145, 2011.
 
27) Kunii Y, et al : Revisiting DARPP-32 in postmortem human brain : changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression. Mol Psychiatry 19 (2) : 192-199, 2014.
 
28) Kunii Y, et al : CHRNA7 and CHRFAM7A mRNAs : Co-Localized and Their Expression Levels Altered in the Postmortem Dorsolateral Prefrontal Cortex in Maj or Psychiatric Disorders. Am J Psychiatry 172 (11) : 1122-1130, 2015.
PubMed
29) Kunii Y, et al : Elevated postmortem striatal t-DARPP expression in schizophrenia and associations with DRD2/ANKK1 polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 53 : 123-128, 2014.
PubMed
30) Hino M, et al : Decreased VEGFR2 expression and increased phosphorylated Akt1 in the prefrontal cortex of individuals with schizophrenia. J Psychiatr Res 82 : 100-108, 2016.
PubMed
P.69 掲載の参考文献
1) Potter D, et al : Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 32 (4) : 692-700, 2006.
PubMed
2) 平野羊嗣, 他 : 音に対する感覚フィルタリング機構. 臨脳波 49 (1) : 56-64, 2007.
Medical*Online
3) Hirano Y, et al : Auditory gating deficit to human voices in schizophrenia a MEG study. Schizophr Res 117 (1) : 61-67, 2010.
PubMed
4) Dalecki A, et al : The relevance of attention in schizophrenia P50 paired stimulus studies. Clin Neurophysiol 127 (6) : 2448-2454, 2016.
PubMed
5) Gaebler A J, et al : Auditory mismatch impairments are characterized by core neural dysfunctions in schizophrenia. Brain 138 : 1410-1423, 2015.
PubMed
6) Javitt D C, et al : Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation : implications for schizophrenia. Proc Natl Acad Sci U S A 93 (21) : 11962-11967, 1996.
PubMed
7) Sutton S, et al : Evoked potential correlates of stimulus uncertainty, Science 150 (3700) : 1187-1188, 1965.
PubMed
8) Jeon Y W, et al : Meta-analysis of P300 and schizophrenia : patients, paradigms, and practical implications, Psychophysiology 40 (5) : 684-701, 2003.
PubMed
9) 前川敏彦, 他 : 双極性障害の臨床神経生理学的研究. 臨精医 37 (10) : 1295-1302, 2008.
Medical*Online
10) Kwon J S, et al : Gamma frequency-range abnormalities to auditory stmulation in schizophrenia. Arch Gen Psychiatry 56 (11) : 1001-1005, 1999.
 
11) Spencer K M, et al : Gamma-band auditory steady-state responses are impaired in first episode psychosis. Biol Psychiatry 64 (5) : 369-375, 2008.
PubMed
12) Hirano Y, et al : Spontaneous Gamma Activity in Schizophrenia. JAMA Psychiatry 72 (8) : 813-821, 2015.
PubMed
13) Hong L E, et al : Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res 70 (2-3) : 293-302, 2004.
 
14) 平河則明, 他 : 神経生理学からみた統合失調症. 臨精医 45 (9) : 1123-1131, 2016.
Medical*Online
15) Levy D L, et al : Eye tracking dysfunction in schizophrenia : characterization and pathophysiology. Curr Top Behav Neurosci 4 : 311-347, 2010.
PubMed
16) Morita K, et al : Eye movement as a biomarker of schizophrenia : Using an integrated eye movement score. Psychiatry Clin Neurosci 71 (2) : 104-114, 2017.
PubMed
17) Franco J G, et al : Smooth pursuit eye movements and schizophrenia literature review. Arch Soc Esp Oftalmol 89 (9) : 361-367, 2014.
PubMed
18) Ikezawa K, et al : Impaired regional hemodynamic response in schizophrenia during multiple prefrontal activation tasks : a two-channel near-infrared spectroscopy study. Schizophr Res 108 (1-3) : 93-103, 2009.
 
19) Takizawa R, et al : Neuroimaging-aided differential diagnosis of the depressive state. Neuroimage 85 : 498-507, 2014.
PubMed
20) Clementz B A, et al : Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers. Am J Psychiatry 173 (4) : 373-384, 2016.
PubMed
P.78 掲載の参考文献
1) Howes O D, et al : The dopamine hypothesis of schizophrenia : version III-the final common pathway. Schizophr Bull 35 (3) : 549-562, 2009.
PubMed
2) Breier A, et al : Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations : evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94 (6) : 2569-2574, 1997.
PubMed
3) Fujiwara Y, et al : Behavioral sensitization to methamphetamine in the rat : an ontogenic study. Psychopharmacology (Berl) 91 (3) : 316-319, 1987.
PubMed
4) Sawaguchi T, et al : DI dopamine receptors in prefrontal cortex : involvement in working memory. Science 251 (4996) : 947-950, 1991.
 
5) Javitt D C, et al : Recent advances in the phencyclidine model of schizophrenia. Am J psychiatry 148 (10) : 1301-1308, 1991.
PubMed
6) Krystal J H, et al : Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (3) : 199-214, 1994
PubMed
7) Lahti A C, et al : Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 (1) : 9-19, 1995.
PubMed
8) Carlen M, et al : A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychlatry 17 (5) : 537-548, 2012.
 
9) Moghaddam B, et al : Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonlst in rats. Science 281 (5381) : 1349-1352, 1998.
PubMed
10) Patil S T, et al : Activation of mGlu2/3 receptors as a new approach to treat schizophrenia : a randomized Phase 2 clinical trial. Nat Med 13 (9) : 1102-1107, 2007.
PubMed
11) Javitt D C, et al : Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Buli 38 (5) : 958-966, 2012.
 
12) Karlsson R M, et al : Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics : rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol Psychiatry 64 (9) : 810-814, 2008.
PubMed
13) Walsh T, et al : Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320 (5875) : 539-543, 2008.
PubMed
P.84 掲載の参考文献
1) 疋田貴俊, 他 : 精神疾患モデル動物の作製と治療法スクリーニング. 実験医増刊 30 (13) : 2074-2079, 2012.
 
2) 毛利彰宏, 他 : グルタミン酸作動性神経系と統合失調症モデル動物. 日薬理誌 127 (1) : 4-8, 2006.
Medical*Online
3) Zuckerman L, et al : Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring a novel neurodevelopmental model of schizophrenia Neuropsychopharmacology 28 (10) : 1778-1789, 2003.
PubMed
4) International Schizophrenia Consortium : Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455 (7210) : 237-241, 2008.
PubMed
5) Stark K L, et al : Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet 40 (6) : 751-760, 2008.
 
6) Sigurdsson T, et al : Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 464 (7289) : 763-767, 2010.
 
7) Hikida T, et al : Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. ProcNatlAcadSciUSA 104 (36) : 14501-14506, 2007.
PubMed
8) Ibi D, et al : Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. Behav Brain Res 206 (1) : 32-37, 2010.
PubMed
9) Niwa M, et al : Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science 339 (6117) : 335-339, 2013.
PubMed
10) Hayashi Y, et al : Impaired hippocampal activity at the goal zone on the place preference task in a DISC1 mouse model. Neurosci Res 106 : 70-73, 2016.
 
11) Morita M, et al : Dopamine D2L receptor is required for visual discrimination and reversal learning. Mol Neuropsychiatry 2 (3) : 124-132, 2016.
PubMed
P.94 掲載の参考文献
1) Logothetis N K, et al : Neurophysiological investigation of the basis of the fMRI signal. Nature 412 (6843) : 150-157, 2001.
PubMed
2) Takahashi H, et al : An fMRI study of differential neural response to affective pictures in schizophrenia. Neuroimage 22 (3) : 1247-1254, 2004.
PubMed
3) Koeda M, et al : Language processing and human voice perception in schizophrenia : a functional magnetic resonance imaging study. Biol Psychiatry 59 (10) : 948-957, 2006.
PubMed
4) Raichle M E, et al : A default mode of brain function. Proc Natl Acad Sci U S A 98 (2) : 676-682, 2001.
PubMed
5) Barkhof F, et al : Resting-state functional MR imaging. a new window to the brain. Radiology 272 (1) : 29-49, 2014.
 
6) Kim B H, et al : Disrupted salience processing involved in motivational deficits for real-life activities in patients with schizophrenia. Schizophr Res 2018 [Epub ahead of print]
 
7) 村井俊哉 : 検査法-C 神経画像検査. 標準精神医学 第6版 (野村総一郎, 他編), p107-115. 医学書院, 東京, 2015.
 
8) Marumo K, et al : Functional abnormalities in the left ventrolateral prefrontal cortex during a semantic fluency task, and their association with thought disorder in patients with schizophrenia. Neuroimage 85 Pt 1 : 518-526, 2014.
 
9) 伊藤浩 : PETによる神経・精神疾患の分子イメージング, PET J 22 : 42-43, 2013.
 
10) 石井辰弥, 他 : 特集1 PETによる神経・精神疾患, の分子イメージング. PET J 23 : 13-15, 2013.
 
11) Yasuno F, et al : Low dopamine d (2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161 (6) : 1016-1022, 2004.
PubMed
12) Nozaki S, et al : Regional dopamine synthesis in patients with schizophrenia using L- [beta-11C] DOPA PET. Schizophr Res 108 (1-3) : 78-84, 2009.
 
13) Okubo Y : Decreased prefrontal dopamine DI receptors in schizophrenia revealed by PET. Nature 385 (6617) : 634-636, 1997.
 
14) Arakawa R, et al : Increase in thalamic binding of [(11) C] PE2I in patients with schizophrenia : a positron emission tomography study of dopamine transporter. J Psychiatr Res 43 (15) : 1219-1223, 2009.
PubMed
P.103 掲載の参考文献
1) Kraepelin E : Dementia Praecox and Paraphrenia (1919). Huntington. 1971 Barclay R M, et al, translated
 
2) Bleuler E : Dementia Praecox or the Group of Schizophrenia. International Universities Press, 1950.
PubMed
3) Rapaport D, et al : Diagnostic Psychological Testing. Year Book Publishers 1945/1946.
 
4) Goldstein G : Cognitive and perceptual dfferences between schizophrenics and organics. Schizophr Bull 4 : 160-185, 1978.
 
5) Heaton R K, et al : Neuropsychological test results associated with psychiatric disorders in adults. Psychol Bull 85 : 141-162, 1978.
PubMed
6) Malec J : Neuropsychological assessment of schizophrenia versus brain damage : a review. J Nerv Ment Dis 166 : 507-517, 1978.
PubMed
7) 松岡恵子, 他 : 日本語版National Adult Reading Test (JART) の作成. 精神医 44 : 503-511, 2002.
 
8) 植月美希, 他 : 統合失調症患者の発病前知能推定に関する日本語版National Adult Reading Test (JART) 短縮版妥当性の検討. 精神医 49 : 17-23, 2007.
 
9) Matsui M, et al : Impairment of story memory organization in patients with schizophrenia. Psychiatry Clin Neurosci 61 (4) : 437-440, Corrigenda 61 (5) : 580, 2007,
 
10) Goldberg T E, et al : Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry 44 : 1008-1014, 1987.
PubMed
11) 鹿島晴雄他 : 慢性分裂病の前頭葉機能に関する神経心理学的検討 Wisconsin Card Sorting Test新修正法による結果. 臨精医 14 : 1479-1489, 1985.
 
12) Matsui M, et al : Schizotypal disorder and schizophrenia : A profile analysis of neuropsychological functioning in Japanese patients. J Int Neuropsychol Soc 13 : 672-682, 2007.
PubMed
13) Kolb B, et al : Performance of schizophrenic patients on tests sensitive to left or right frontal temporal, and parietal function in neurologic patients. J Nerv Ment Dis 171 : 435-443, 1983.
PubMed
14) Chapman L J, et al : The measurement of differential deficits. J Psychiatr Res 14 : 303-311, 1978.
PubMed
15) Saykin A J, et al : Neuropsychological function in schizophrenia ; selective impairment in memory and learning. Arch Gen Psychiatry 48 : 618-624, 1991.
PubMed
16) Heinrichs R W, et al : Neurocognitive deficit in schizophrenia ; Aquantitative review of the evidence. Neuropsychology 12 : 426-445, 199 &
 
17) Dickinson D, et al : Overlooking the Obvious. Arch Gen Psychiatry 64 (5) : 532-542, 2007.
PubMed
18) Schaefer J, et al : The global cognitive impairment in schizophrenia : Consistent over decades and around the world. Schizophr Res 150 (1) : 42-50, 2013.
PubMed
19) Rund BR : A review of longitudinai studies of cognitie functions in schizophrenia patients. Schizophr Bull 24 : 425-435, 1998.
 
20) Shmukler A B, et al : Long-term trajectories of cognitive deficits in schizophrenia : A critical overview. Eur Psychiatry 30 : 1002-1010, 2015.
PubMed
21) Jones P, et al : Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344 (8934) : 1398-1402, 1994.
PubMed
22) Fuller R, et al : Longitudinal assessment of pre-morbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 159 (7) : 1183-1189, 2002.
 
23) Reichenberg A, et al : Static and dynamic cognitive deficits in childhood preceding adult schizophrenia : A 30-year study. Am J Psychiatry 167 (2) : 160-169, 2010.
PubMed
24) Oie M, et al : Neurocognition and functional outcome in early-onset schizophrenia and attention-deficit/hyperactivity disorder : a 13-year follow-up. Neuropsychol 25 : 25-35, 2011.
 
25) Russell A J, et al : Schizophrenia and the myth of intellectual decline. American J Psychiatry 154 : 635-639, 1997.
 
26) Bora E, et al : Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis : do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull 40 (4) : 744-755, 2014.
PubMed
27) Torgalsboen A K, et al : Neurocognitive predictors of remission of symptoms and social and role functioning in the early course of first-episode schizophrenia. Psychiatry Res 216 (1) : 1-5, 2014.
PubMed
28) Bonner-Jackson A, et al : Neurocognition in schizophrenia : A 20-year multi-follow-up of the course of processing speed and stored knowledge. Compr Psychiatry 51 : 471-479, 2010.
PubMed
29) Sitskoorn M M, et al : Cognitive deficits in relatives of patients with schizophrenia : a meta-analysis. Schizophr Res 71 : 285-295, 2004.
PubMed
30) Siever L J, et al : The pathophysiology of schizophrenia disorders : perspectives from the spectrum. Am J Psychiatry 161 : 398-413, 2004.
PubMed
31) Brewer W J, et al : Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 162 : 71-78, 2005,
PubMed
32) Lencz T, et al : Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 59 : 863-871, 2006.
PubMed
33) Fusar-Poli P, et al : Cognitive functioning in prodromal psychosis : a meta-analysis. Arch Gen Psychiatry 69 : 562-571, 2012.
PubMed
P.112 掲載の参考文献
1) ブロイラー著, 飯田真, 他訳 : 早発性痴呆または精神分裂病群. 医学書院, 東京, 1974.
 
2) ベイトソン著, 佐藤良明訳 : 精神の生態学. 思索社, 東京, 1990/新思索社, 東京, 2000.
 
3) 中安信夫 : 統合失調症の病態心理 要説 : 状況意味失認-内因反応仮説. 星和書店, 東京, 2013.
 
4) シュナイダー著, 針間博彦訳 : 新版 臨床精神病理学. 文光堂, 東京, 2007.
 
5) ブランケンブルグ著, 木村敏他訳 : 自明性の喪失-分裂病の現象学. みすず書房, 東京, 1978.
 
6) 木村敏 : 新編 分裂病の現象学. 筑摩書房, 東京, 2012.
 
7) ヤスパース著, 西丸四方訳 : 精神病理学原論. みすず書房, 東京, 1971.
 
8) Gallagher S : Neurocognitive models of schizo-phrenia : A neurophenomenological critique. Psychopathology 37 : 8-19, 2004.
 
9) Blakemore S J, et al : The perception of self-produced sensory sdmuli in patients with auditory hallucinations and passivity experiences : evidence for a breakdown in self-monitoring. Psychol Med 5 : 1131-1139, 2000.
PubMed
10) 安永浩 : 分裂病症状機構に関する一仮説-ファントム論について. 分裂病の精神病理 1 (土居健郎編). pp187-218. 東京大学出版会, 東京, 1972.
 
11) American Psychiatric Association監, 高橋三郎, 他訳 : DSM-IV-TR 精神疾患の診断・統計マニュアル新訂版. 医学書院, 東京, 2003.
 
12) American Psychiatric Association監, 日本精神神経学会 (日本語版監修) : DSM-5 精神疾患の診断・統計マニュアル. 医学書院, 東京, 2014.
 
13) Spitzer M : On defining delusions. Compr Psychiatry 31 : 377-397, 1990.
PubMed
14) 衣笠隆幸 : 力動精神医学. 統合失調症 (日本統合失調症学会監, 福田正人, 他編). pp291-300. 医学書院, 東京, 2013.
 
15) 加藤正明, 他編 : 新版精神医学事典. pp867-868, 弘文堂, 東京, 1993.
 
16) 加藤正明, 他編 : 新版精神医学事典. pp855-856, 弘文堂, 東京, 1993.
 
17) ラカン著, 小出浩之, 他訳 : 精神病 (上・下). 岩波書店, 東京, 1987.
 

第3章 治療・支援

P.119 掲載の参考文献
1) 日本神経精神薬理学会 : 統合失調症 薬物治療ガイドライン, p1-19. 医学書院, 東京, 2016.
 
2) Buchanan R W, et al : The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36 (1) : 71-93, 2010.
PubMed
3) Leucht S, et al : Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophreniat a multiple-treatments meta-analysis. Lancet 382 (9896) : 951-962, 2013.
PubMed
4) 岸太郎, 他 : 初発精神病性障害. 統合失調症 薬物治療ガイドライン (日本神経精神薬理学会), p1-19. 医学書院東京, 2016.
 
5) Andreasen N C, et al : Remission in schizophrenia : proposed criteria and rationale for consensus. Am J Psychiatry 162 (3) : 441-449, 2005.
PubMed
6) Emsley R, et al : Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 163 (4) : 743-745, 2006.
PubMed
7) 伊賀淳一, 他 : 再発・再燃時. 統合失調症 薬物治療ガイドライン (日本神経精神薬理学会), p21-37. 医学書院,東京, 2016.
 
8) Weiden P J : Understanding and addressing adherence issues in schizophrenia : from theory to practice. J Clin Psychiatry 68 (Suppl 14) : 14-19, 2007.
 
9) Higashi K : Medication adherence in schizophrenia : factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 3 (4) : 200-218, 2013.
PubMed
10) Lehman A F, et al : Practice guideline for the treatment of patients with schizophrenia second edition. Am J psychiatry 161 (2 Suppl) : 1-56, 2004.
 
11) Psychosis and schizophrenia in adults : treatment and management. NICE Clinical Guidelines 178, 2014.
PubMed
12) Hogarty G E, et al : Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Sys 37 (9) : 494-500, 1976.
 
13) Leucht S, et al : Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and meta-analysis. Lancet 379 (9831) : 2063-2071, 2012.
PubMed
14) Sampson S, et al : Intermittent drug techniques for schizophrenia Cochrane Database Syst Rev 7 : CD006196, 2013.
PubMed
15) 伊藤侯輝, 他 : 維持期治療. 統合失調症 薬物治療ガイドライン (日本神経精神薬理学会), p40-61. 医学書院, 東京, 2016.
 
16) Torniainen M, et al : Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41 (3) : 656-663, 2015.
PubMed
17) Green M F, et al : From perception to functional outcome in schizophrenia : modeling the role of ability and motivation. Arch Gen Psychiatry 69 (12) : 1216-1224, 2012.
PubMed
18) Millan M J, et al : Negative symptoms of schizophrenia : clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment Eur Neuropsychopharmacol 24 (5) : 645-692, 2014.
PubMed
19) Davis M C, et al : Psychopharmacology of the negative symptoms : current status and prospects for progress. Eur Neuropsychopharmacol 24 (5) : 788-799, 2014.
PubMed
20) Miyamoto S, et al : Pharmacological treatment of schizophrenia : a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17 (12) : 1206-1227, 2012.
PubMed
P.129 掲載の参考文献
1) Hasan A, et al : World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1 : update 20120n the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13 (5) : 318-378, 2012.
PubMed
2) Gillespie A L, et al : Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry 17 (1) : 12, 2017.
PubMed
3) Leonhard K : Aufteilung der endogenen Psychosen. 1957.
 
4) Shorter E, et al : Shock Therapy : A history of Electroconvulsive Treatment in Mental Illness. Rutgers University Press, New Brunswick, 2007. [川島啓嗣, 他 : <電気ショック> の時代 : ニューロモデュレーションの系譜. みすず書房, 東京, 2018.]
 
5) Astrup C : The effects of ataraxic drugs on schizophrenic subgroups related to experimental findings. Acta Psychiatr Scand Suppl 34 (136) : 388-393, 1959.
PubMed
6) Fish F : The Influence of the Tranquilizers on the Leonhard Schizophrenic Syndromes. Encephale 53 : SUPPL : 245-249, 1964.
 
7) Witton K : Efficacy of ECT following prolonged use of psychotropic drugs. Am J psychiatry 119 : 79, 1962.
PubMed
8) Kane J, et al : Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 (9) : 789-796, 1988.
PubMed
9) Kennedy C J, et al : Regressive electric-shock in schizophrenics refractory to other shock therapies. Psychiatr Q 22 (2) : 317-320, 1948.
PubMed
10) Suzuki T, et al : Defining treatment-resistant schizophrenia and response to antipsychotics : a review and recommendation. Psychiatry Res 197 (1-2) : 1-6, 2012.
PubMed
11) ノバルテイスファーマ株式会社 : クロザリル(R) 添付文書. 2013.
 
12) 日本臨床精神薬理学会 クロザピン検討委員会編 : クロザピン (クロザリル) 適正使用ガイダンス改訂第12版. 協和企画, 東京, 2018.
 
13) Lennox B R, et al : Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis : a case-control study. Lancet Psychiatry 4 (1) : 42-48, 2017.
PubMed
14) Oviedo-Salcedo T, et al : Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders. Br J psychiatry 28 : 1-3, 2018.
 
15) Deville C, et al : Dissociative disorders : between neurosis and psychosis. Case Rep Psychiatry : 425892, 2014.
PubMed
16) Renard S B, et al : Unique and Overlapping Symptoms in Schizophrenia Spectrum and Dissociative Disorders in Relation to Models of Psychopathology : A Systematic Review. Schizophr Bull 43 (1) : 108-121, 2017.
PubMed
17) Bradley E A, et al : Psychiatric conditions and behavioural problems in adolescents with intellectual disabilities : correlates with autism. Can J Psychiatry 56 (2) : 102-109, 2011.
PubMed
18) Brockington I : Menstrual psychosis. World Psychiatry 4 (1) : 9-17, 2005.
PubMed
19) 山下格 : 若年周期精神病. 精神科治療 25 (4) : 617-622, 2000.
 
20) 日本神経精神薬理学会編 : 統合失調症薬物治療ガイドライン. 医学書院, 東京, 2016.
 
21) Kishimoto T, et al : Long-acting injectable versus oral antipsychotics in schizophrenia : a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74 (10) : 957-965, 2013.
PubMed
22) Tiihonen J, et al : Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29823 Patients With Schizophrenia. JAMA Psychiatry 74 (7) : 686-693, 2017.
 
23) Tiihonen J, et al : 11-year follow-up of mortality in patients with schizophrenia : a population-based cohort study (FIN11 study). Lancet 374 (9690) : 620-627, 2009.
PubMed
24) Wheeler A, et al : Outcomes for schizophrenia patients with clozapine treatment : how good does it get? JPsychopharmacol 23 (8) : 957-965, 2009.
PubMed
25) Galletly C, et al : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J psychiatry 50 (5) : 410-472, 2016.
PubMed
26) Remington G, et al : Guidelines for the Pharmacptherapy of Schizophrenia in Adults. Can J Psychiatry 62 (9) : 604-616, 2017.
PubMed
27) Samara M T, et al : Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia. JAMA Psychiatry 73 : 199-210, 2016.
PubMed
28) Spears N M, et al : Clozapine treatment in polydipsia and intermittent hyponatremia. J Clin Psychiatry 57 (3) : 123-128, 1996.
PubMed
29) Canuso C M, et al : Clozapine restores water balance in schizophrenic patients with polydipsia-hyponatremia syndrome. J Neuropsychiatry Clin Neurosci 11 (1) : 86-90, 1999.
PubMed
30) Leucht S, et al : Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis. Lancet 382 (9896) : 951-962, 2013.
PubMed
31) Claghorn J, et al : The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7 (6) : 377-384, 1987.
PubMed
32) Ronaldson K J, et al : Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine : a case-control study. Schizophr Res 141 (2-3) : 173-178, 2012.
 
33) Pui-yin Chung J, et al : The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can J psychiatry 53 (12) : 857-862, 2008.
 
34) Meltzer H Y : Clozapine : balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 6 (3) : 134-144, 2012.
PubMed
35) 飯塚幸彦, 他 : 治療抵抗性統合失調症を対象としたclozapineの製造販売後調査結果 (中間集計). 臨精薬理 19 (6) : 859-876, 2016.
 
36) Small J G, et al : Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 23 (3) : 223-228, 2003.
PubMed
37) Taylor D, et al (eds) : The Maudsley Prescribing Guidelines in Psychiatry, 12th Edition. Wily-Blackwell, UK, 2015.
 
38) 藤井康夫編 : クロザピン100のQ&A. 星和書店, 東京, 2014.
 
39) Ahmed S, et al : Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia : A comparative meta-analysis. Heliyon 3 (11) : e00429, 2017.
PubMed
40) Grover S, et al : Combined use of clozapine and ECT : a review. Acta Neuropsychiatr 27 (3) : 131-142, 2015.
PubMed
41) Petrides G, et al : Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia : A Prospective, Randomized Study. Am J Psychiatry 172 : 52-58, 2014.
PubMed
42) Taylor D M, et al : Augmentation of clozapine with a second antipsychotic-a meta-analysis. Acta Psychiatr Scand 125 (1) : 15-24, 2012.
PubMed
43) Barber S, et al : Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev 3 : CD006324, 2017.
PubMed
44) Veerman S R, et al : Clozapine augmented with glutamate modulators in refractory schizophrenia : a review and metaanalysis. Pharmacopsychiatry 47 (6) : 185-194, 2014.
PubMed
45) Waite J, et al : The ECT Handbook (3rd edition). RCPsych Publications, London, 2013.
 
46) National Institute for Health and Care Excellence (NICE) : Guidance on the use of electroconvulsive therapy. 2003. <https://www.nice.org.uk/guidance/ta59>
 
47) Barnes T R, et al : Evidence-based guidelines for the pharmacological treatment of schizophrenia : recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25 (5) : 567-620, 2011.
PubMed
48) 本橋伸高, 他 : 電気けいれん療法 (ECT) 推奨事項改訂版. 精神誌 115 (6) : 586-600, 2013.
 
49) Mankad M V, et al : Clinical Manual of Electroconvulsive Therapy. American Psychiatric Publishing, Washington DC, 2010.
 
50) Luchini F, et al : Electroconvulsive therapy in catatonic patients : Efficacy and predictors of response. World J Psychiatly 5 (2) : 182-192, 2015.
 
51) Hatta K, et al : Maximal response to electroconvulsive therapy for the treatment of catatonic symptoms. J ECT 23 (4) : 233-235, 2007.
PubMed
52) Gibson R C, et al : Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev Oct 08 (4) : CD006570, 2008.
 
53) Rasmussen S A, et al : Catatonia : Our current understanding of its diagnosis, treatrnent and pathophysiology. World J Psychiatry 6 (4) : 391-398, 2016.
 
54) Pompili M, et al : Indications for electroconvulsive treatment in schizophrenia a systematic review. Schizophr Res 146 (1-3) : 1-9, 2013.
 
55) Trollor J N, et al : Electroconvulsive treatment of neuroleptic malignant syndrome : a review and report of cases. Aust N Z J Psychiatry 33 (5) : 650-659, 1999.
PubMed
56) Davis J M, et al : Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. Convuls Ther 7 (2) : 111-120, 1991.
PubMed
57) Shibasaki C, et al : Factors associated with the risk of relapse in schizophrenic patients after a response to electroconvulsive therapy : a retrospective study. Neuropsychiatr Dis Treat 11 : 67-73, 2015.
PubMed
58) Suzuki K, et al : One-year outcome after response to ECT in middle-aged and elderly patients with intractable catatonic schizophrenia. JECT 20 (2) : 99-106, 2004.
 
59) Hustig H, et al : ECT rekindles pharmacological response in schizophrenia. Eur Psychiatry 24 (8) : 521-525, 2009.
PubMed
60) Flamarique I, et al : Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders : is it a safe and effective combination? J Clin Psychopharmacol 32 (6) : 756-766, 2012.
PubMed
61) Chanpattana W, et al : Continuation ECT in treatment-resistant schizophrenia : a controlled study. J ECT 15 (3) : 178-192, 1999.
PubMed
62) Devanand D P, et al : Absence of cognitive impairment after more than 100 lifetime ECT treatments. Am J Psychiatry 148 (7) : 929-932, 1991.
PubMed
63) Lally J, et al : Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia : A systematic review and meta-analysis. Schizophr Res 171 (1-3) : 215-224, 2016.
PubMed
64) Turner D T, et al : A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis. Schizophr Bull 2017. [Epub ahead of print]
 
65) Chouinard G, et al : Antipsychotic-Induced Dopamine Supersensitivity Psychosis : Pharmacology, Criteria, and Therapy. Psychother Psychosom 86 (4) : 189-219, 2017.
PubMed
66) Miyashita M, et al : Clinical features of schizophrenia with enhanced carbonyl stress. Schizophr Bull 40 (5) : 1040-1046, 2014.
PubMed
P.139 掲載の参考文献
1) Beck AT, et al : うつ病の認知療法 (坂野雄二監訳), p41-46. 岩崎学術出版社, 東京, 2007.
 
2) 堀越勝 : 精神療法の基本 : 支持から認知行動療法まで, p260. 医学書院, 東京, 2012.
 
3) Wright J H, et al : 認知行動療法トレーニングブック (大野裕訳), p1-30. 医学書院, 東京, 2007.
 
4) Wright J H, et al : 認知行動療法トレーニングブック 短時間の外来診療編 (大野裕訳), p241-277. 医学書院, 東京, 2011.
 
5) Emma Williams : 統合失調症のための集団認知行動療法 (菊池安希子監訳), p31-207. 星和書店, 東京, 2008.
 
P.146 掲載の参考文献
1) 池淵恵美 : 統合失調症の社会的認知 : 脳科学と心理社会的介入の架橋を目指して. 精神誌 114 : 489-507, 2012.
 
2) Green M F, et al : Neurocognitive deficits and functional outcome in schizophrenia : are we measuring the "right stuff"? Schizophr Bull 26 : 119-136, 2000.
PubMed
3) Heinrichs R W : Meta-analysis and the science of schizophrenia : variant evidence or evidence of variants? Neurosci Biobehav Rev 28 : 379-394, 2004.
PubMed
4) Kahn R S, et al : Schizophrenia is a cognitive illness : time for a change in focus. JAMA Psychiatry 70 : 1107-1112, 2013.
PubMed
5) Nuechterlein K H, et al : The early longitudinal course of cognitive deficits in schizophrenia. J Clin Psychiatry 75 (2) : 25-29, 2014.
 
6) Penn D L, et al : Social cognition in schizophrenia. Psych Bull 121 : 114-132, 1997.
 
7) 根本隆洋 : 精神疾患と認知機能 (山内俊雄編集統括), p284-291. 新興医学出版社, 東京, 2009.
 
8) Penn D L, et al : Social cognition in schizophreniat an overview. Schizophr Bull 34 : 408-411, 2008.
PubMed
9) Fett A K, et al : The relationship between neurocognition and social cognition with functional outcomes in schizophrenia : a meta-analysis. Neurosci Biobehav Rev 35 : 573-588, 2011.
PubMed
10) Benedict R H, et al : Remediation of attention deficits in chronic schizophrenic patients : a preliminary study. Br J Clin Psychol 28 (2) : 187-188, 1989.
PubMed
11) Koh S D, et al : Affective encoding and consequent remembering in schizophrenic young adults. J Abnorm Psychol 85 (2) : 156-166, 1976.
PubMed
12) Steffy R A, et al : Relation between latency and redundancy-associated deficit in schizophrenic reaction time performance. J Abnorm Psychol 89 (3) : 419-427, 1980.
PubMed
13) Medalia A, et al : Cognitive remediation in schizophrenia. Neuropsycho Rev 19 (3) : 353-364, 2009.
 
14) Wykes T, et al : A meta-analysis of cognitive remediation for schizophrenia : methodology and effect sizes. Am J Psychiatry 168 (5) : 472-485, 2011.
PubMed
15) Cella M, et al : Cognitive remediation for negative symptoms of schizophrenia : Anetwork meta-analysis. Clin Psychol Rev 52 : 43-51, 2017.
 
16) アリス・メダリア : 精神疾患における認知機能障害の矯正法 (中込和幸監訳). 星和書店, 東京, 2008.
 
17) デイビッド・ロバーツ : 社会認知ならびに対人関係のトレーニング治療マニュアル (中込和幸監訳). 星和書店, 東京, 2011.
 
18) 池澤聰 : 認知機能障害とそのリハビリテーション. 臨精医 45 (8) : 1023-1030, 2016.
Medical*Online
19) Roberts D L, et al : A randomized, controlled trial of Social Cognition and Interaction Training (SCIT) for outpatients with schizophrenia spectrum disorders. Br J Clin Psychol 53 (3) : 281-298, 2014.
PubMed
20) ロバート・ポール・リバーマン著, 西園昌久総監訳, 池淵恵美監訳, SST普及協会訳 : 精神障害と回復-リバーマンのリハビリテーション・マニュアル. 星和書店, 東京, 2011.
 
21) Wallace C J, et al : A review and critique of social skills training with schizophrenic patients. Schizophr Bull 6 (1) : 42-63, 1980.
 
22) Liberman R P, et al : Recovery from schizophrenia a concept in search of research. Psychiatr Serv 56 (6) : 735-742, 2005.
PubMed
23) 安西信雄 : 生活技能訓練 (social skills training) による分裂病の再発防止. 脳と精の医 3 (2) : 175-183, 1992.
 
24) Choque Olsson N, et al : Social skills training for children and adolescents with autism spectrum disorder : A randomized controlled trial. J Am Acad Child Adolesc Psychiatry 56 (7) : 585-592, 2017.
PubMed
25) 渡辺弥生 : 健全な学校風土をめざすユニヴァーサルな学校予防教育-免疫力を高めるソーシャル・スキル・トレーニングとソーシャル・エモーショナル・ラーニングー. 教心理年報 54 : 126-141, 2015.
 
26) Yutani M, et al : Social skills training improves clinical residents'communication skills. Kitasato Med J 46 : 53-59, 2016.
 
27) 八木原律子 : 更生保護施設におけるSST実践の現状と課題-更生保護施設での聞き取り調査をもとにして-. 明治学院大学社会学部付属研究所 44 : 49-56, 2014.
 
28) Dogan R K, et al : Parent-implemented behavioral skills training of social skills. J Appl Behav Anal 50 (4) : 805-818, 2017.
PubMed
29) Zubin J, et al : Vulnerability-A new view of schizophrenia. J Abn Psychology 86 (2) : 103-126, 1977.
 
30) Kopelowicz A, et al : Recent advances in social skills training for schizophrenia. Schizophr Bull 32 (Suppl 1) : 12-23, 2006.
 
31) Turner D T, et al : A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis. Schizophr Bull 2017 [Epub ahead of print]
 
32) Almerie M Q, et al : Social skills programmes for schizophrenia. Cochrane Database Syst Rev 9 (6) : CD009006, 2015.
 
33) Kurtz M M, et al : Social skills training and computer-assisted cognitive remediation in schizophrenia Schizophr Res 162 (1-3) : 35-41, 2015.
 
P.161 掲載の参考文献
1) 厚生労働省 平成29年障害者雇用状況の集計結果 <http://www.mhlw.go.jp/stf/houdou/0000187661.html>.
 
P.168 掲載の参考文献
1) 福井次矢, 他監 : Minds診療ガイドライン作成の手引き 2014. 医学書院, 東京, 2014.
 
2) 精神医学講座担当者会議 : 統合失調症治療ガイドライン 第2版. 医学書院, 東京, 2008.
 
3) 日本神経精神薬理学会 : 統合失調症薬物治療ガイドライン. 医学書院, 東京, 2016.
 
4) 三宅誕実, 他 : 【統合失調症薬物治療のアップデイト】統合失調症薬物治療ガイドラインの考え方と概要 日病薬師会誌 52 (2) : 164-166, 2016.
 
5) 稲田健 : 【統合失調症の治療ガイドライン】日本神経精神薬理学会の統合失調症薬物治療ガイドラインとその位置づけ. 臨精薬理 20 (12) : 1433-1439, 2017.
 
6) 富永武男, 他 : 【最新の精神科薬物治療ガイドライン】統合失調症の最新薬物治療ガイドライン. 臨精薬理 14 (6) : 985-992, 2011.
 
P.170 掲載の参考文献
1) Bresee L C, et al : Schizophr Res 117 : 75, 2010.
PubMed
2) Nielsen R E, et al : Schizophr Res 146 (1-3) : 22, 2013.
 
3) McEvoy J P. et al : Schizophr Res 80 : 19, 2005.
 
4) Sugai T, et al : Schizophr Res 171 : 68, 2016.
PubMed
5) Sugai T, et al : PLoS One 11 (11) : e0166429, 2016,
PubMed
6) Sugawara N, et al : PLoS One 9 (1) : e86826, 2014.
PubMed
7) Sugawara N, et al : Neuropsychiatr Dis Treat 12 : 427, 2016.
PubMed
8) Sugawara N, et al : J Psychiatr Res 97 : 77, 2018.
PubMed
9) Sugai T, et al : BMJ Open 5 (12) : e008720, 2015.
PubMed

第4章 法との関連

P.180 掲載の参考文献
1) 町野朔 : 心神喪失者等医療観察法案と触法精神障害者の治療を受ける権利. 触法精神障害者の処遇 (町野朔, 他編), p229-243. 信山社, 東京, 2005.
 
2) 斎藤正彦 : 精神保健法における強制入院制度の諸問題. 精神障害者の強制治療 (西山詮編), P37-57. 金剛出版, 東京, 1994.
 
3) 広田伊蘇夫 : 精神保健福祉法概論. 臨床精神医学講座 22 精神医学と法 (松下正明監), p49-59. 中山書店, 東京, 1997.
 
4) 吉田哲彦 : 日本における精神医療行政と法. 臨床精神医学講座 22 精神医学と法 (松下正明監), p73-85. 中山書店, 東京, 1997.
 
5) 岡田靖雄 : 日本精神科医療史. 医学書院, 東京, 2002.
 
6) 金子嗣郎, 他 : 日本における精神医療関連法規の歴史. 臨床精神医学講座 22 精神医学と法 (松下正明監), p37-48. 中山書店, 東京, 1997.
 
7) 岩波明 : 精神障害者をどう裁くか. 光文社新書, 東京, 2009.
 
8) 高柳功, 他 : 精神科領域におけるインフォームド・コンセント-現状と課題. 精神医 38 : 997-1005, 1996.
 
9) 諸冨伸夫 : 精神保健福祉法改正と入院制度. 臨精医 44 (3) : 319-324, 2015.
Medical*Online
10) 中島公博 : Topics Q&A時流解説 Q精神保健福祉法改定後の現状について教えてください. Depres J 4 (1) : 26-27, 2016.
 
11) 武田康久 : 精神保健及び精神障害者福祉に関する法律と精神保健福祉行政の現状. 平成29年度全国自治体病院協議会精神保健指定医研修会 更新・第59回.
 
12) OECD : Hospital beds (indicator), doi : 10.1787/0191328e-en, 2017.
 
13) 五十嵐禎人 : 海外の非自発的入院制度. 精神臨サービス 17 (3) : 301-307, 2017.
 
14) 川本哲郎 : 精神科入院と精神医療審査会. 臨精医 44 (3) : 383-386, 2015.
Medical*Online
15) 平田豊明 : 措置入院制度の歴史と現状. 精神臨サービス 17 (3) : 281-287, 2017.
 
16) 中谷陽二 : 医療の視点からみた触法精神障害者問題. 触法精神障害者の処遇 (町野朔, 他編), p203-213. 信山社, 東京, 2005.
 
17) 中谷陽二 : 触法精神障害者に関する臨床精神医学的研究. 触法精神障害者の処遇 (町野朔, 他編), p28-32. 信山社, 東京, 2005,
 
18) 村上優 : 司法と医療の狭間にある事例にどう対応するか. 精神臨サービス 17 (3) : 245-250, 2017.
 
P.189 掲載の参考文献
1) 平成27年度日本医療研究開発機構研究費 (障害者対策総合研究開発事業 (精神障害分野)). 「医療観察法における, 新たな治療介入法や, 行動制御に係る指標の開発等に関する研究」 (主任研究者 : 平林直次)報告書.
 
2) 平成29年度における, 日本医療研究開発機構研究費 (障害者対策総合研究開発事業 (精神障害分野)) の分担研究「指定入院医療機関退院後の予後に影響を与える因子の同定に関する研究」 (分担研究者 : 松田太郎)報告書.
 
3) 平成29年度における, 日本医療研究開発機構研究費 (障害者対策総合研究開発事業 (精神障害分野)) の分担研究「治療抵抗性統合失調症に対する効果的かつ安全な治療法の確立に関する研究」 (分担研究者 : 来住由樹) 報告書
 
P.196 掲載の参考文献
1) Leucht S, et al : Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and meta-analysis. Lancet 379 (9831) : 2063-2071, 2012.
PubMed
2) 日本神経精神薬理学学会 : 統合失調症薬物治療ガイドライン. 2017.
 
3) 星野貴俊 : 統合失調症患者における自動車運転行動実態と日常的認知機能. 精神医 56 (1) : 21-27, 2014.
 
4) Waller J A : Chronic medical conditions and traffic safety : review of the California experience. N Engl J Med 273 (26) : 1413-1420, 1965.
PubMed
5) Crancer A Jr, et al : The mentally ill as motor vehicle operators. Am J Psychiatry 126 (6) : 807-813, 1969.
PubMed
6) Edlund M J, et al : Accidents among schizophrenic outpatients. Compr Psychiatry 30 (6) : 522-526, 1989.
PubMed
7) Chang C M, et al : Psychotropic drugs and risk of motor vehicle accidents : apopulation-based case-control study. Br J Clin Pharmacol 75 (4) : 1125-1133, 2013.
 
8) Kagerer S, et al : Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study. Neuropsychobiology 47 (4) : 212-218, 2003.
PubMed
9) Brunnauer A, et al : The impact of antipsychotics on psychomotor performance with regards to car driving skills. J Clin Psychopharmacol 24 (2) : 155-160, 2004.
PubMed
10) Soyka M, et al : Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. J psychiatr Res 39 (1) : 101-108, 2005.
PubMed
11) Brunnauer A, et al : Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics. Eur Arch Psychiatry Clin Neurosci 259 (8) : 483-489, 2009.
PubMed
12) Assessing fitness to drive-A guide for medical professionals. Driver & Vihicle Licensing Agency, 2016.
 
13) Assessing Fitness to Drive for commercial and private vehicle drivers. Austroads, 2016.
 
P.204 掲載の参考文献
1) 梁瀬まや, 他 : 裁判員裁判における鑑定人尋問. 精神医 59 : 901-911, 2017.
 
2) 中谷陽二 : 法と精神医学. 精神誌 109 : 882-886, 2007.
 
3) 最高裁判所事務総局家庭局 : 成年後見制度における鑑定書作成の手引. 31 pp. 2011. <http://www.courts.go.jp/vcms_lf/30475001.pdf>
 
4) 昼田源四郎 : 日本古代と近世における狂気と犯罪. 精神障害者の責任能力. 法と精神医学の対話 (中谷陽二, 編). p221-236. 金剛出版, 東京, 1993.
 
5) 岡田幸之 : 刑事責任能力再考-操作的診断と可知論的判断の適用の実際. 精神誌 107 : 920-935, 2005.
 
6) 福島章 : 精神鑑定とは何か-何をどう診断するか? p237. 講談社, 東京, 1995.
 
7) 井上俊宏, 他 : 精神障害と犯罪 精神分裂病. 臨床精神医学講座 19 司法精神医学・精神鑑定 (風祭元他編). p119-130. 中山書店, 東京, 1998.
 
8) 中田修 : 精神分裂病の犯行のみせかけの了解可能性. 精神障害者の責任能力 法と精神医学の対話 (中谷陽二, 編). p25-41. 金剛出版, 東京, 1993.
 
9) 高岡健 : 精神鑑定とは何か 責任能力論を超えて. p208, 明石書店, 東京, 2010.
 
10) 高田知二 : 市民のための精神鑑定入門 裁判員裁判のために. p223. 批評社, 東京, 2012.
 
11) 五十嵐禎人 (編) : 刑事責任鑑定のすべて. p204. 金剛出版, 東京, 2008.
 
12) 中谷陽二 : 精神鑑定の実際と鑑定書. 臨床精神医学講座 19 司法精神医学・精神鑑定 (風祭元他編). p95-105. 中山書店, 東京, 1998.
 
13) 西山詮 : 刑事精神鑑定の実際. p458, 新興医学出版社, 東京, 2004.
 
14) 岡田幸之 : 責任能力判断の構造と着眼点-8ステップと7つの着眼点-. 精神誌 115 : 1064-1070.
 
15) 前田泰 : 民事精神鑑定と成年後見法. p376. 日本評論社, 東京, 2000.
 
16) 最高裁判所事務総局家庭局 : 成年後見制度における診断書作成の手引. 11 pp. 2015. <http://www.courts.go.jp/vcms_lf/H2512sindan.pdf>
 

第5章 まとめ

P.213 掲載の参考文献
1) 村井俊哉 : 統合失調症の概念・病態・治療. 外来精神医療 18 : 29-33, 2018.
 
2) Harrington A : The fall of the schizophrenogenic mother. Lancet 379 : 1292-1293, 2012.
PubMed
3) 三嶋亮, 他 : 現代の診断基準からみた統合失調症概念. 臨精神医 45 : 985-991, 2016.
 
4) Zachar P : A Metaphysics of Psychopathology. MIT Press, Cambridge, 2014.
 
5) Schaefer J, et al : The global cognitive impairment in schizophrenia consistent over decades and around the world. Schizophr Res 50 : 42-50, 2013.
 
6) Heila H, et al : The clinical epidemiology of suicide in schizophrenia. In : The Epidemiology of Schizophrenia (Murray R, et al, eds), pp288-316. Cambridge University Press, Cambridge, 2003.
 

書評

最近チェックした商品履歴

Loading...